A phase 3 randomized, double-blind, placebo-controlled trial of ganitumab or placebo in combination with gemcitabine as first-line therapy for metastatic adenocarcinoma of the pancreas: the GAMMA trial

C.S. Fuchs; S. Azevedo; T. Okusaka; J.-L. Van Laethem; L.R. Lipton; H. Riess; C. Szczylik; M.J. Moore; M. Peeters; G. Bodoky; M. Ikeda; B. Melichar; R. Nemecek; S. Ohkawa; A. Świeboda-Sadlej; S.A. Tjulandin; E. Van Cutsem; R. Loberg; V. Haddad; J.L. Gansert; B.A. Bach; A. Carrato

doi:10.1093/annonc/mdv027

A phase 3 randomized, double-blind, placebo-controlled trial of ganitumab or placebo in combination with gemcitabine as first-line therapy for metastatic adenocarcinoma of the pancreas: the GAMMA trial

Annals of Oncology ◽

10.1093/annonc/mdv027 ◽

2015 ◽

Vol 26 (5) ◽

pp. 921-927 ◽

Cited By ~ 78

Author(s):

C.S. Fuchs ◽

S. Azevedo ◽

T. Okusaka ◽

J.-L. Van Laethem ◽

L.R. Lipton ◽

...

Keyword(s):

Controlled Trial ◽

Metastatic Adenocarcinoma ◽

First Line ◽

Phase 3 ◽

Double Blind ◽

Double Blind Placebo ◽

First Line Therapy ◽

Line Therapy ◽

Adenocarcinoma Of The Pancreas

Download Full-text

Gamma (Gemcitabine and Amg 479 for Metastatic Adenocarcinoma of the Pancreas): a Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial of Ganitumab Plus Gemcitabine (G) or Placebo Plus G as First-Line Therapy for Metastatic Pancreatic Cancer

Annals of Oncology ◽

10.1016/s0923-7534(20)33245-2 ◽

2012 ◽

Vol 23 ◽

pp. ix255

Author(s):

C. Fuchs ◽

S. Azevedo ◽

L. Lipton ◽

A. Carrato ◽

J. Gansert ◽

...

Keyword(s):

Pancreatic Cancer ◽

Controlled Trial ◽

Metastatic Adenocarcinoma ◽

First Line ◽

Phase 3 ◽

Double Blind ◽

Double Blind Placebo ◽

First Line Therapy ◽

Line Therapy ◽

Adenocarcinoma Of The Pancreas

Download Full-text

Rilomet-1: an International Phase 3 Multicenter Randomized Double-Blind Placebo-Controlled Trial of Rilotumumab Plus Epirubicin, Cisplatin and Capecitabine (Ecx) As First Line Therapy in Patients with Advanced Met-Positive Gastric or Gastroesophageal Junction (G/Gej) Adenocarcinoma

Annals of Oncology ◽

10.1093/annonc/mdu334.126 ◽

2014 ◽

Vol 25 ◽

pp. iv250 ◽

Cited By ~ 2

Author(s):

D. Cunningham ◽

S. Al-Batran ◽

I. Davidenko ◽

D. Ilson ◽

A.M. Murad ◽

...

Keyword(s):

Controlled Trial ◽

Gastroesophageal Junction ◽

First Line ◽

Phase 3 ◽

Double Blind ◽

Double Blind Placebo ◽

First Line Therapy ◽

Line Therapy

Download Full-text

Fluvastatin in the first-line therapy of acute coronary syndrome: results of the multicenter, randomized, double-blind, placebo-controlled trial (the FACS-trial)

Trials ◽

10.1186/1745-6215-11-61 ◽

2010 ◽

Vol 11 (1) ◽

Cited By ~ 14

Author(s):

Petr Ostadal ◽

David Alan ◽

Jiri Vejvoda ◽

Jiri Kukacka ◽

Milan Macek ◽

...

Keyword(s):

Acute Coronary Syndrome ◽

Controlled Trial ◽

First Line ◽

Double Blind ◽

Double Blind Placebo ◽

Coronary Syndrome ◽

First Line Therapy ◽

Line Therapy

Download Full-text

Abstract S6-01: Phase 3, randomized, double-blind, placebo-controlled multicenter trial of daily everolimus plus weekly trastuzumab and paclitaxel as first-line therapy in women with HER2+ advanced breast cancer: BOLERO-1

10.1158/1538-7445.sabcs14-s6-01 ◽

2015 ◽

Cited By ~ 4

Author(s):

Sara A Hurvitz ◽

Fabrice Andre ◽

Zefei Jiang ◽

Zhimin Shao ◽

Silvia P Neciosup ◽

...

Keyword(s):

Breast Cancer ◽

Advanced Breast Cancer ◽

Multicenter Trial ◽

Advanced Breast ◽

First Line ◽

Phase 3 ◽

Double Blind ◽

Double Blind Placebo ◽

First Line Therapy ◽

Line Therapy

Download Full-text

Rilotumumab plus epirubicin, cisplatin, and capecitabine as first-line therapy in advanced MET-positive gastric or gastro-oesophageal junction cancer (RILOMET-1): a randomised, double-blind, placebo-controlled, phase 3 trial

The Lancet Oncology ◽

10.1016/s1470-2045(17)30566-1 ◽

2017 ◽

Vol 18 (11) ◽

pp. 1467-1482 ◽

Cited By ~ 112

Author(s):

Daniel V T Catenacci ◽

Niall C Tebbutt ◽

Irina Davidenko ◽

André M Murad ◽

Salah-Eddin Al-Batran ◽

...

Keyword(s):

First Line ◽

Phase 3 ◽

Double Blind ◽

Double Blind Placebo ◽

First Line Therapy ◽

Line Therapy

Download Full-text

Ramucirumab versus placebo as second-line treatment in patients with advanced hepatocellular carcinoma following first-line therapy with sorafenib (REACH): a randomised, double-blind, multicentre, phase 3 trial

The Lancet Oncology ◽

10.1016/s1470-2045(15)00050-9 ◽

2015 ◽

Vol 16 (7) ◽

pp. 859-870 ◽

Cited By ~ 344

Author(s):

Andrew X Zhu ◽

Joon Oh Park ◽

Baek-Yeol Ryoo ◽

Chia-Jui Yen ◽

Ronnie Poon ◽

...

Keyword(s):

Hepatocellular Carcinoma ◽

Advanced Hepatocellular Carcinoma ◽

Line Treatment ◽

Second Line ◽

First Line ◽

Phase 3 ◽

Double Blind ◽

Multicentre Phase ◽

First Line Therapy ◽

Line Therapy

Download Full-text

195TiP A phase 3, randomized, double-blind study of epacadostat plus pembrolizumab vs pembrolizumab as first-line therapy for metastatic non-small cell lung cancer (mNSCLC) expressing high PD-L1 levels (ECHO-305/KEYNOTE-654)

Journal of Thoracic Oncology ◽

10.1016/s1556-0864(18)30468-4 ◽

2018 ◽

Vol 13 (4) ◽

pp. S116-S117

Author(s):

L. Paz-Ares ◽

S. Rubin ◽

Y. Zhao ◽

L. Xu ◽

A. Samkari ◽

...

Keyword(s):

Lung Cancer ◽

Small Cell Lung Cancer ◽

Small Cell ◽

Double Blind Study ◽

Small Cell Lung ◽

First Line ◽

Phase 3 ◽

Double Blind ◽

First Line Therapy ◽

Line Therapy

Download Full-text

Ramucirumab with cisplatin and fluoropyrimidine as first-line therapy in patients with metastatic gastric or junctional adenocarcinoma (RAINFALL): a double-blind, randomised, placebo-controlled, phase 3 trial

The Lancet Oncology ◽

10.1016/s1470-2045(18)30791-5 ◽

2019 ◽

Vol 20 (3) ◽

pp. 420-435 ◽

Cited By ~ 58

Author(s):

Charles S Fuchs ◽

Kohei Shitara ◽

Maria Di Bartolomeo ◽

Sara Lonardi ◽

Salah-Eddin Al-Batran ◽

...

Keyword(s):

First Line ◽

Phase 3 ◽

Double Blind ◽

First Line Therapy ◽

Line Therapy

Download Full-text

1609 Final results from PAVES, a phase 3, randomized, double-blind, placebo-controlled trial of pegfilgrastim in patients (pts) receiving first-line FOLFOX or FOLFIRI and bevacizumab for locally advanced or metastatic colorectal cancer (LA/mCRC) (NCT00911170)

European Journal of Cancer ◽

10.1016/s0959-8049(16)30697-9 ◽

2015 ◽

Vol 51 ◽

pp. S241

Author(s):

T. Pinter ◽

P.K. Morrow ◽

A. Cesas ◽

A. Croitoru ◽

J. Decaestecker ◽

...

Keyword(s):

Colorectal Cancer ◽

Metastatic Colorectal Cancer ◽

Controlled Trial ◽

Locally Advanced ◽

First Line ◽

Phase 3 ◽

Double Blind ◽

Double Blind Placebo

Download Full-text

A randomised, double-blind, placebo-controlled trial of trametinib, an oral MEK inhibitor, in combination with gemcitabine for patients with untreated metastatic adenocarcinoma of the pancreas

European Journal of Cancer ◽

10.1016/j.ejca.2014.04.024 ◽

2014 ◽

Vol 50 (12) ◽

pp. 2072-2081 ◽

Cited By ~ 145

Author(s):

Jeffrey R. Infante ◽

Bradley G. Somer ◽

Joon Oh Park ◽

Chung-Pin Li ◽

Max E. Scheulen ◽

...

Keyword(s):

Controlled Trial ◽

Mek Inhibitor ◽

Metastatic Adenocarcinoma ◽

Double Blind ◽

Double Blind Placebo ◽

Adenocarcinoma Of The Pancreas

Download Full-text